(Bloomberg) -- Bank of America Corp. and BNP Paribas SA are on the verge of winning lead roles arranging Sanofi’s separation of its consumer-health business, according to people familiar with the matter, in one of the year’s most sought-after banking assignments. Most Read from BloombergIsrael Rejects a Cease-Fire Plan for Gaza Embraced by HamasAt $2 Million Per Minute, Treasuries Mint Cash Like Never BeforeEx-Trump Controller Says Cohen Repaid From Personal AccountTruce Talks Drag as Hamas Hits
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript May 2, 2024 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $9.55 EPS, expectations were $10.17. Regeneron Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to […]
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.